Sangamo Therapeutics (SGMO) Misses Q4 EPS by 8c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $2.04 million versus the consensus estimate of $8.11 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• PagerDuty, Inc. (PD) Tops Q2 EPS by 1c; offers guidance
• BofA sees mixed signals for European software from US SaaS